

Elsevier Editorial System(tm) for International Journal of Cardiology
Manuscript Draft

Manuscript Number:

Title: Chronic Obstructive Pulmonary Disease—an Independent Risk Factor for Long-term Cardiac and Cardiovascular Mortality in Patients with Ischemic Heart Disease

Article Type: Original Article

Keywords: Chronic obstructive pulmonary disease, Ischemic heart disease, prognosis, Cardiac death, Cardiovascular death

Corresponding Author: Dr Kei Nishiyama,

Corresponding Author's Institution: Kyoto University Graduate School of Medicine

First Author: Kei Nishiyama

Order of Authors: Kei Nishiyama; Takeshi Morimoto, MD PhD; Satoshi Shizuta, MD ; Takahiro Doi, MD; Toru Kita, MD PhD; Takeshi Kimura, MD PhD

Manuscript Region of Origin: JAPAN

Abstract: Background:

Limited data are available on long-term mortality and morbidity of patients with chronic obstructive pulmonary disease (COPD) and ischemic heart disease. We examined how COPD affects the long-term mortality and morbidity after undergoing percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG).

Methods:

We analyzed 9877 consecutive patients who underwent their first elective PCI (n = 6878) and CABG (n = 2999) in 2000-2002 at 30 institutions listed in the CREDO-Kyoto registry.

Results:

COPD was diagnosed in 240 patients (2.4%). In-hospital mortality (1.3% vs. 1.2%, $p = 0.972$) did not differ between patients with and without COPD. During long-term follow up (42.8 months), 906 patients (9.4%) died, 517 (5.3%) of whom died of cardiovascular death and 376 (3.9%), of cardiac death. At 3 years, the unadjusted survival rate and the rates of freedom from cardiovascular death and cardiac death were 92.1%, 95.3%, and 96.5% in the total population and 82.8%, 91.7%, and 92.1% in patients with COPD respectively. Log-rank test indicated that COPD was associated with higher incidence of all-cause mortality ($p < 0.0001$), cardiovascular death ($p = 0.0002$), and cardiac death ($p < 0.0001$). Multivariate analyses indicated that COPD was an independent predictor of all-cause mortality (hazard ratio 1.36, $p = 0.0003$), cardiovascular death (hazard ratio 1.28, $p = 0.0407$), and cardiac death (hazard ratio 1.48, $p = 0.003$).

Conclusions:

COPD is an independent risk factor for long-term cardiac and cardiovascular mortality in patients with ischemic heart disease.

Suggested Reviewers:

1
2
3 **Chronic Obstructive Pulmonary Disease—an Independent Risk Factor for**
4
5
6 **Long-term Cardiac and Cardiovascular Mortality in Patients with Ischemic Heart**
7
8
9 **Disease**
10

11
12
13
14
15
16 Kei Nishiyama^a, M.D.
17

18
19 Takeshi Morimoto^b, M.D., PhD.
20

21
22 Satoshi Shizuta^a, M.D.
23

24
25 Takahiro Doi^a, M.D.
26

27
28 Toru Kita^a, M.D., PhD.
29

30
31 Takeshi Kimura^a, M.D., PhD.
32
33
34
35
36
37

38 ^aDepartment of Cardiovascular Medicine, Kyoto University Graduate School of
39
40
41 Medicine
42

43
44 ^bIntegrated Clinical Education Center, Kyoto University Hospital
45
46
47
48
49

50
51 Word count: 3641
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3 Key words:
4
5

6 Chronic obstructive pulmonary disease, Ischemic heart disease, prognosis, Cardiac
7
8 death, Cardiovascular death
9
10

11
12
13
14
15
16 All authors have read and approved the manuscript. No conflicts of interest exist among
17
18 any of the authors in this study.
19
20
21

22
23
24
25 Address for correspondence:
26

27
28 Kei Nishiyama
29

30
31
32 Department of Cardiovascular Medicine, Kyoto University Graduate School of
33
34
35 Medicine
36

37
38 54 Kawaharamachi, Shogoin, sakyo-ku, Kyoto 606-8397, Japan
39

40
41 TEL: 81-7-5751-3198, FAX: 81-7-5751-3299
42

43
44 E-mail: keinishi@kuhp.kyoto-u.ac.jp
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3 **Structured abstract (Word count = 248)**
4
5

6 Background:

7
8
9 Limited data are available on long-term mortality and morbidity of patients with chronic
10 obstructive pulmonary disease (COPD) and ischemic heart disease. We examined how
11
12 COPD affects the long-term mortality and morbidity after undergoing percutaneous
13
14 coronary intervention (PCI) and coronary artery bypass grafting (CABG).
15
16
17
18
19
20
21

22 Methods:

23
24
25 We analyzed 9877 consecutive patients who underwent their first elective PCI (n =
26
27 6878) and CABG (n = 2999) in 2000–2002 at 30 institutions listed in the
28
29 CREDO-Kyoto registry.
30
31
32
33

34 Results:

35
36
37 COPD was diagnosed in 240 patients (2.4%). In-hospital mortality (1.3% vs. 1.2%, p =
38
39 0.972) did not differ between patients with and without COPD. During long-term follow
40
41 up (42.8 months), 906 patients (9.4%) died, 517 (5.3%) of whom died of cardiovascular
42
43 death and 376 (3.9%), of cardiac death. At 3 years, the unadjusted survival rate and the
44
45 rates of freedom from cardiovascular death and cardiac death were 92.1%, 95.3%, and
46
47 96.5% in the total population and 82.8%, 91.7%, and 92.1% in patients with COPD
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65 respectively. Log-rank test indicated that COPD was associated with higher incidence of

1
2
3 all-cause mortality ($p < 0.0001$), cardiovascular death ($p = 0.0002$), and cardiac death (p
4
5
6 < 0.0001). Multivariate analyses indicated that COPD was an independent predictor of
7
8
9 all-cause mortality (hazard ratio 1.36, $p = 0.0003$), cardiovascular death (hazard ratio
10
11
12 1.28, $p = 0.0407$), and cardiac death (hazard ratio 1.48, $p = 0.003$).

13
14
15
16 **Conclusions:**

17
18
19 COPD is an independent risk factor for long-term cardiac and cardiovascular mortality
20
21
22 in patients with ischemic heart disease.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3 **Body of paper**
4
5
6
7
8

9 **Introduction**
10

11
12
13 Chronic obstructive pulmonary disease (COPD) is a common comorbidity
14
15
16 among patients undergoing percutaneous coronary intervention (PCI) and coronary
17
18 artery bypass grafting (CABG) ¹⁻³. Although some cohort studies have revealed that
19
20 patients with COPD have a significantly higher risk of in-hospital mortality and
21
22 long-term all-cause mortality following PCI and CABG ⁴⁻¹⁴, the effects of COPD on
23
24 long-term mortality and morbidity in patients with ischemic heart disease have not been
25
26 adequately demonstrated. To examine these effects, we evaluated the long-term
27
28 outcomes of patients undergoing coronary revascularization in a large-scale multicenter
29
30 registry in Japan.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3 **Materials and methods**
4
5

6 The Coronary Revascularization Demonstrating Outcome Study in Kyoto
7
8
9 (CREDO-Kyoto) registry has collected data on the potential risk factors and outcomes
10
11
12 in 9877 consecutive patients who underwent their first elective PCI (n = 6878) and
13
14 CABG (n = 2999) at the 30 institutions between 2000 and 2002 in Japan. Patients with
15
16 acute myocardial infarction within 1 week prior to the index procedure were excluded.
17
18
19 The relevant review boards or ethics committees in all 30 participating centers
20
21
22 (Appendix A) approved the research protocol. A description of the design and study
23
24
25 protocol has been previously published¹⁵ and the study protocol is concordant with the
26
27
28 guidelines for epidemiologic studies issued by the Ministry of Health, Labor and Welfare
29
30
31 of Japan. In order to examine whether COPD is an independent predictor of all-cause
32
33
34 mortality, cardiovascular death, and cardiac death following PCI and CABG, we
35
36
37 performed post hoc analysis of the data collected from 9756 consecutive patients who
38
39
40 survived their first elective PCI (n = 6846) and CABG (n = 2910). The primary end
41
42
43 point was all-cause mortality, cardiovascular death, and cardiac death. Demographic and
44
45
46 angiographic characteristics before coronary intervention, and procedural data were
47
48
49 collected from hospital charts or databases in each center by independent clinical
50
51
52 research coordinators (Appendix B) according to prespecified definitions. Data in this
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3 registry include patient demographics (e.g., age and gender), potential risk factors, and
4
5
6 comorbidities (e.g., COPD, stroke, hypertension, and current smoking status) that have
7
8
9 been demonstrated to be related to short-term and long-term outcomes.
10

11
12 All procedural decisions, including the technique of revascularization and
13
14 device selection, were made at the discretion of the patient, the physician, and the
15
16 surgeon performing PCI and CABG.
17
18
19
20
21
22
23
24

25 *Definition*

26
27
28 A patient was considered to have COPD if it was listed as a comorbid condition
29
30 in our database and its diagnosis was confirmed by a simple test called spirometry,
31
32 which measures how deeply a person can breathe and how fast air can move into and
33
34 out of his or her lungs. Such a diagnosis should be considered in any patient who has
35
36 symptoms of cough, sputum production, or dyspnea (difficult or labored breathing),
37
38 and/or a history of exposure to risk factors for the disease. In cases where spirometry is
39
40 unavailable, the diagnosis of COPD should be made using all available tools. Clinical
41
42 symptoms and signs such as abnormal shortness of breath and increased forced
43
44 expiratory time can be used to arrive at the diagnosis. A low peak flow is consistent with
45
46 but not specific to COPD because it can be caused by other lung diseases and by poor
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3 performance during testing. Chronic cough and sputum production often precede the
4
5
6 development of airflow limitation by many years, although not all individuals with
7
8
9 cough and sputum production go on to develop COPD. Congestive heart failure was
10
11
12 diagnosed on the basis of clinical signs (New York Heart Association [NYHA] \geq II).
13
14
15 Diabetes or hypertension was considered to be present if the patients were previously
16
17
18 diagnosed by another physician or if they were being treated with either insulin or oral
19
20
21 antidiabetic drugs, or antihypertensive drugs respectively. Patients were considered to
22
23
24 have a history of myocardial infarction if previously diagnosed by electrocardiogram or
25
26
27 coronary angiography. The criteria for the diagnosis of periprocedural myocardial
28
29
30 infarction were the appearance of new Q waves and an increase in creatine kinase to
31
32
33 ≥ 2.0 times the upper limit of normal occurring ≤ 24 hours after PCI. Stroke at the
34
35
36 baseline included asymptomatic stroke detected by non-invasive imaging modalities.
37
38
39 Peripheral vascular disease was considered to be present when patients were being
40
41
42 treated for carotid, aortic, and/or other peripheral vascular diseases or were scheduled
43
44
45 for surgical or endovascular interventions. Left ventricular ejection fraction was
46
47
48 measured either by contrast left ventriculography or echocardiography. Patients with left
49
50
51 ventricular ejection fraction $\leq 40\%$ were deemed to have left ventricular dysfunction.
52
53
54
55
56
57 Chronic renal disease was identified when the creatinine clearance estimated by
58
59
60
61
62
63
64
65

1
2
3 Cockcroft-Gault formula was less than 60 mL/min. Anemia was defined as blood
4
5
6 hemoglobin level < 12 g/dL.
7
8

9
10 Long-term follow up was performed using outpatient visits and chart review. A
11
12 central adjudication committee reviewed all deaths in a blinded fashion by using source
13
14 documentation provided by the site investigators.
15
16
17
18
19
20
21

22 *Statistical analysis*

23
24

25 Standard descriptive statistics (proportions and 2 tests) were used to list patient
26
27 and disease characteristics by subgroup. Statistical analysis of categorical variables was
28
29 carried out using cross tables with the Pearson χ^2 test. Survival curves were estimated
30
31 using the Kaplan-Meier method and compared with the log-rank statistics. To determine
32
33 the baseline risk factors for the incidence of all-cause mortality, cardiovascular death,
34
35 and cardiac death, we developed Cox proportional hazards models for the following 24
36
37 potential variables: COPD, the technique of revascularization, gender, body mass index,
38
39 emergency procedure, prior myocardial infarction, congestive heart failure, stroke,
40
41 peripheral artery disease, chronic atrial fibrillation, malignancy, hypertension, diabetes
42
43 without insulin therapy, diabetes with insulin therapy, dialysis, chronic renal disease,
44
45 anemia, current smoking status, left ventricular dysfunction, chronic total occlusion of
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3 the coronary artery, proximal left anterior descending coronary artery disease, left main
4
5
6 coronary artery disease, age, and triple vessel disease. All continuous variables were
7
8
9 dichotomized so as to agree with the proportional assumptions according to the
10
11
12 predetermined clinical contexts. We plotted log (time) vs. log[-log (survival)] stratified
13
14
15 by each significant risk factor and evaluated whether the plotted lines were parallel¹⁶.
16
17
18 The variables for which p values were less than 0.05 in univariate analyses and
19
20
21 proportional assumptions were generally fair were included in the multivariate analyses.
22
23
24 We developed multivariate Cox proportional hazards models that controlled for
25
26
27 significant risk factors while testing for significant differences in long-term results. The
28
29
30 appropriateness of the proportional hazards assumption for these variables has been
31
32
33 attested elsewhere (Kimura manuscript). All analyses were performed with JUMP
34
35
36
37
38 version 6.0.3 (SAS; Cary, NC).
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3 **Results**
4
5

6 COPD was diagnosed in 240 patients (2.4%) on the basis of the baseline
7 characteristics, which are shown in Table 1. Patients with COPD were more likely to
8 have congestive heart failure, stroke, peripheral artery disease, chronic renal disease,
9 anemia, and left ventricular dysfunction. They also tended to be older and had a lower
10 average body mass index. Patients without COPD were more likely to be women and
11 having diabetes that did not require insulin therapy. No difference was detected in the
12 current smoking status in the 2 groups.
13
14
15
16
17
18
19
20
21
22
23
24
25
26

27
28 In-hospital mortality (1.3% vs. 1.2%, $p = 0.9724$) and in-hospital Q-wave
29 myocardial infarction incidence (0.8% vs. 0.9%, $p = 0.8572$) did not differ between the
30 groups (Table 2).
31
32
33
34
35
36

37
38 A total of 98% and 95% patients continued to attend follow-up examinations at
39 the end of 1 and 2 years respectively. During long-term follow up (median follow-up
40 period = 42.8 months), 906 patients (9.4%) died, 517 (5.3%) of which died of
41 cardiovascular death and 376 (3.9%), of cardiac death. Of the total population, 265
42 patients (2.7%) suffered acute myocardial infarction, and 468 (4.8%) suffered stroke. Of
43 the patients with COPD, 50 (21.3%) died, of which 24 (10.3%) died of cardiovascular
44 death, and 22 (9.4%), of cardiac death. A total of 6 COPD patients (2.6%) suffered acute
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3 myocardial infarction, and 11 (4.7%) suffered stroke. At 3 years, the unadjusted survival
4
5
6 rate and the rates of freedom from cardiovascular death and cardiac death were 92.1%,
7
8
9 95.3%, and 96.5% in the total population and 82.8%, 91.7%, and 92.1% in patients with
10
11
12 COPD, respectively.
13
14

15
16 Univariate analysis revealed that COPD was associated with higher all-cause
17
18 mortality ($p < 0.0001$), cardiovascular death ($p = 0.0002$), and cardiac death ($p <$
19
20
21
22 0.0001); Kaplan-Meier survival curves are presented in Figure 1.
23
24

25
26 Multivariate analyses (considering the baseline characteristics and the results of
27
28 univariate analyses) indicated that COPD was an independent predictor of all-cause
29
30
31 mortality, cardiovascular death, and cardiac death after PCI and CABG (Table 3).
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3 **Discussion**
4
5

6 Smoking as a risk factor is common to both COPD and ischemic heart disease;
7
8 hence, these 2 diseases often coexist ^{17, 18}. Previous studies have shown that patients
9
10 with COPD have a significantly higher risk of long-term all-cause mortality after PCI
11
12 and CABG ⁵⁻¹⁴. The manner in which COPD affects long-term mortality and morbidity
13
14 in patients with ischemic heart disease remains unresolved. We analyzed 9877
15
16 consecutive patients who underwent their first elective PCI (n = 6878) and CABG (n =
17
18 2999) at 30 institutions in Japan. Univariate and multivariate analyses in this study
19
20 indicated that COPD was an independent predictor of all-cause mortality. To our
21
22 knowledge, this study is the first to show that patients with COPD have a significantly
23
24 higher risk of cardiac and cardiovascular death following PCI and CABG.
25
26
27
28
29
30
31
32
33
34
35
36
37

38 The manner in which COPD affects the incidence of long-term adverse cardiac
39
40 events after coronary revascularization is not quite clear. It was reported that patients
41
42 affected by COPD have an increased risk of acute atherothrombotic events, and that this
43
44 increase is independent of smoking and other cardiovascular risk factors. Further,
45
46 bronchial inflammation reportedly spreads to the systemic circulation and is known to
47
48 play a key role in plaque formation and rupture ¹⁹. While the current smoking status did
49
50 not differ between patients with and without COPD, this study reported that patients
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3 with COPD were more likely to have peripheral artery disease and stroke as
4
5
6 pre-operative comorbidities. Exacerbation of COPD may overtax an already diseased
7
8
9 heart because of hypoxemia and increased work of breathing. It was reported that severe
10
11
12 hypoxemia can worsen cardiac ischemia in patients with ischemic heart disease^{20,21}. On
13
14
15 the other hand, exacerbation of ischemic heart disease can further impair gas exchange
16
17
18 by incrementally increasing airway resistance or reducing mixed venous
19
20
21 oxyhemoglobin saturation. Cardiac arrhythmias are frequent among patients with
22
23
24 COPD. Previous studies reported widely various incidence of arrhythmia and
25
26
27 arrhythmia related death in patients with COPD and it was reported that about ten
28
29
30 percent of patients with COPD suffer from SCD²²⁻²⁶. However, the role of serious
31
32
33 ventricular arrhythmias in these situations is unknown²⁷. An association between severe
34
35
36 COPD and increased QTc dispersion was reported, which has been reported as a marker
37
38
39 of ventricular electrical instability²⁸. It is not clear whether treating asymptomatic
40
41
42 ventricular arrhythmia can reduce the incidence of SCD or not in patients with
43
44
45 COPD²²⁻²⁶. This study demonstrated that COPD was associated with a higher incidence
46
47
48 of long-term cardiac and cardiovascular mortality and morbidity. However additional
49
50
51 interventional therapy for COPD was not recorded in our database, and so further study
52
53
54 may be needed to investigate whether intervention for COPD can improve long-term
55
56
57
58
59
60
61
62
63
64
65

1
2
3 mortality and morbidity from cardiac causes in patients with ischemic heart disease.
4
5

6 Though it was reported that the severity of COPD might affect in-hospital
7
8
9
10 outcomes after PCI and CABG, we found that patients with COPD undergoing elective
11
12
13 PCI and CABG had in-hospital morbidity and mortality rates comparable with those of
14
15
16 controls after first elective PCI and CABG in this study. Previously it was demonstrated
17
18
19 that post-CABG mortality was largely higher in patients with severe COPD receiving
20
21
22 steroids than that of patients without COPD, however post-CABG mortality of patients
23
24
25 with mild or moderate COPD was similar to that of patients without COPD^{4, 5} .
26
27
28 However the severity of COPD was not well examined because pulmonary function test
29
30
31 was not recorded in our database, and so further study may be needed to investigate the
32
33
34 relationship between severity of COPD and short- and long-term mortality in patients
35
36
37 with ischemic heart disease.
38
39
40

41 This study has some limitations. The definition of COPD in our study was
42
43
44 consistent with that in many other studies ^{1, 2, 9-11}, and 240 patients with COPD were
45
46
47 identified in our study, which accounted for 2.4% of total population. However, the
48
49
50 definition of COPD might be slightly lenient because the results of pulmonary function
51
52
53 tests were not recorded in our database. Because ventricular function was evaluated
54
55
56 before PCI or CABG, substantial recovery of ventricular function may have occurred in
57
58
59
60
61
62
63
64
65

1
2
3 some patients with left ventricle dysfunction with a concomitant decrease in the risk of
4
5
6 all-cause mortality and cardiac death. In this study, we found that after the first elective
7
8
9 PCI and CABG, the in-hospital morbidity rates in patients with COPD and control were
10
11
12 comparable. It has been reported that the severity of COPD might affect in-hospital
13
14
15 outcomes after PCI and CABG ^{4,5}; however, the severity of COPD was not adequately
16
17
18 determined in our study because the results of pulmonary function tests were not
19
20
21 recorded in our database. Moreover, we have no information regarding the adjunctive
22
23
24 pharmacotherapy after discharge and the duration of some of these comorbidities; these
25
26
27 parameters may influence long-term mortality and morbidity.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Acknowledgments

We are indebted to the clinical research coordinators for data collection and to Miss Yoko Kasakura for secretarial assistance.

1
2
3 **References**
4
5

- 6 1. Grover FL, Johnson RR, Marshall G, Hammermeister KE. Factors predictive of
7 operative mortality among coronary artery bypass subsets. *Ann Thorac Surg*
8
9 1993;56(6):1296-306; discussion 1306-7.
10
11
12
13
14
15 2. Roques F, Nashef SA, Michel P, Gauducheau E, de Vincentiis C, Baudet E, et al.
16 Risk factors and outcome in European cardiac surgery: analysis of the
17
18 EuroSCORE multinational database of 19030 patients. *Eur J Cardiothorac Surg*
19
20 1999;15(6):816-22; discussion 822-3.
21
22
23
24
25
26
27 3. Gardner SC, Grunwald GK, Rumsfeld JS, Mackenzie T, Gao D, Perlin JB, et al.
28 Risk factors for intermediate-term survival after coronary artery bypass grafting.
29
30
31
32
33
34
35
36
37
38
39 4. Samuels LE, Kaufman MS, Morris RJ, Promisloff R, Brockman SK. Coronary
40 artery bypass grafting in patients with COPD. *Chest* 1998;113(4):878-82.
41
42
43
44 5. Michalopoulos A, Geroulanos S, Papadimitriou L, Papadakis E, Triantafyllou K,
45
46
47
48
49
50
51
52
53
54
55
56
57
58 6. Canver CC, Nichols RD, Kroncke GM. Influence of age-specific lung function
59
60
61
62
63
64
65

1
2
3 on survival after coronary bypass. *Ann Thorac Surg* 1998;66(1):144-7.
4
5

- 6
7 7. Clough RA, Leavitt BJ, Morton JR, Plume SK, Hernandez F, Nugent W, et al.
8
9 The effect of comorbid illness on mortality outcomes in cardiac surgery. *Arch*
10
11
12
13 *Surg* 2002;137(4):428-32; discussion 432-3.
14
15
- 16 8. Rosenthal GE, Vaughan Sarrazin M, Hannan EL. In-hospital mortality following
17
18 coronary artery bypass graft surgery in Veterans Health Administration and
19
20 private sector hospitals. *Med Care* 2003;41(4):522-35.
21
22
23
- 24 9. Medalion B, Katz MG, Cohen AJ, Hauptman E, Sasson L, Schachner A.
25
26 Long-term beneficial effect of coronary artery bypass grafting in patients with
27
28 COPD. *Chest* 2004;125(1):56-62.
29
30
31
32
- 33 10. van Domburg RT, Takkenberg JJ, van Herwerden LA, Venema AC, Bogers AJ.
34
35 Short-term and 5-year outcome after primary isolated coronary artery bypass
36
37 graft surgery: results of risk stratification in a bilocation center. *Eur J*
38
39
40
41
42
43
44
45 *Cardiothorac Surg* 2002;21(4):733-40.
46
47
- 48 11. DeRose JJ, Jr., Toumpoulis IK, Balaram SK, Ioannidis JP, Belsley S, Ashton RC,
49
50 Jr., et al. Preoperative prediction of long-term survival after coronary artery
51
52 bypass grafting in patients with low left ventricular ejection fraction. *J Thorac*
53
54
55
56
57
58
59
60
61
62
63
64
65 *Cardiovasc Surg* 2005;129(2):314-21.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
12. Renzetti AD, Jr., McClement JH, Litt BD. The Veterans Administration cooperative study of pulmonary function. 3. Mortality in relation to respiratory function in chronic obstructive pulmonary disease. *Aspen Emphysema Conf* 1968;9:367-78.
 13. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. *N Engl J Med* 2004;350(10):1005-12.
 14. Selvaraj CL, Gurm HS, Gupta R, Ellis SG, Bhatt DL. Chronic obstructive pulmonary disease as a predictor of mortality in patients undergoing percutaneous coronary intervention. *Am J Cardiol* 2005;96(6):756-9.
 15. Kimura T, Morimoto T, Furukawa Y, Nakagawa Y, Shizuta S, Ehara N, et al. Long-term outcomes of coronary-artery bypass graft surgery versus percutaneous coronary intervention for multivessel coronary artery disease in the bare-metal stent era. *Circulation* 2008;118:S199-S209.
 16. Collet D. *Modelling Survival Data in Medical Research*. 2nd Ed ed; 2003.
 17. Behar S, Panosh A, Reicher-Reiss H, Zion M, Schlesinger Z, Goldbourt U. Prevalence and prognosis of chronic obstructive pulmonary disease among

1
2
3 5,839 consecutive patients with acute myocardial infarction. SPRINT Study
4
5
6 Group. Am J Med 1992;93(6):637-41.
7
8

9
10 18. Sin DD, Man SF. Chronic obstructive pulmonary disease as a risk factor for
11
12 cardiovascular morbidity and mortality. Proc Am Thorac Soc 2005;2(1):8-11.
13
14

15
16 19. Fimognari FL, Scarlata S, Conte ME, Incalzi RA. Mechanisms of
17
18 atherothrombosis in chronic obstructive pulmonary disease. Int J Chron Obstruct
19
20 Pulmon Dis 2008;3(1):89-96.
21
22

23
24
25 20. Entwistle MD, Sommerville D, Tandon AP, Jones JG. Effect of hypoxaemia on
26
27 the resting electrocardiogram (ECG) in patients with cardiac ischaemia. Ann
28
29 Acad Med Singapore 1994;23(4):460-4.
30
31

32
33
34
35 21. Gill NP, Wright B, Reilly CS. Relationship between hypoxaemic and cardiac
36
37 ischaemic events in the perioperative period. Br J Anaesth 1992;68(5):471-3.
38
39

40
41 22. Kleiger RE, Senior RM. Longterm electrocardiographic monitoring of
42
43 ambulatory patients with chronic airway obstruction. Chest 1974;65(5):483-7.
44
45

46
47
48 23. Buch P, Friberg J, Scharling H, Lange P, Prescott E. Reduced lung function and
49
50 risk of atrial fibrillation in the Copenhagen City Heart Study. Eur Respir J
51
52 2003;21(6):1012-6.
53
54

55
56
57 24. Shih HT, Webb CR, Conway WA, Peterson E, Tilley B, Goldstein S. Frequency
58
59

1
2
3 and significance of cardiac arrhythmias in chronic obstructive lung disease.
4
5
6 Chest 1988;94(1):44-8.
7
8

9
10 25. Fuso L, Incalzi RA, Pistelli R, Muzzolon R, Valente S, Pagliari G, et al.
11
12 Predicting mortality of patients hospitalized for acutely exacerbated chronic
13
14 obstructive pulmonary disease. Am J Med 1995;98(3):272-7.
15
16
17

18
19 26. Hudson LD, Kurt TL, Petty TL, Genton E. Arrhythmias associated with acute
20
21 respiratory failure in patients with chronic airway obstruction. Chest
22
23
24 1973;63(5):661-5.
25
26
27

28
29 27. Burrows B, Earle RH. Course and prognosis of chronic obstructive lung disease.
30
31 A prospective study of 200 patients. N Engl J Med 1969;280(8):397-404.
32
33
34

35
36 28. Sarubbi B, Esposito V, Ducceschi V, Meoli I, Grella E, Santangelo L, et al.
37
38 Effect of blood gas derangement on QTc dispersion in severe chronic obstructive
39
40 pulmonary disease: evidence of an electropathy? Int J Cardiol
41
42
43
44 1997;58(3):287-92.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure legend

Unadjusted Kaplan-Meier Event-free Survival Curves for All-cause Mortality (Panel A),
Cardiovascular death (Panel B), and Cardiac Death (Panel C).

COPD = chronic obstructive pulmonary disease

1
2
3 **Appendices**
4

5
6 **Appendix A. List of participating centers and investigators**
7

8
9

Centers	Investigators
Fukuroi Municipal Hospital	Katsuo Okazaki
Hamamatsu Rosai Hospital	Masaaki Takahashi
	Teiji Oda
Hikone Municipal Hospital	Shigeo Matsui
	Naohiro Ohashi
Himeji Medical Center	Eiichi Matsuyama
	Makoto Kadoya
Hyogo Prefectural Amagasaki Hospital	Yoshiki Takatsu
	Shinichi Nomoto
	Kazuaki Kataoka
Japanese Red Cross Society, Wakayama Medical Center	Hajime Kotoura
	Masaki Aota
	Akira Miura
Juntendo University Shizuoka Hospital	Satoru Suwa
Kagoshima University Medical and Dental Hospital	Chuwa Tei

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Ryuzo Sakata

Shuichi Hamasaki

Hiroyuki Yamamoto

Kansai Denryoku Hospital

Takeshi Aoyama

Takahiro Sakurai

Kishiwada City Hospital

Mitsuo Matsuda

Masahiko Onoe

Yuzo Takeuchi

Kitano Hospital

Ryuji Nohara

Kimisato Nakano

Kobe City Medical Center General Hospital

Shigefumi Morioka

Yukikatsu Okada

Kenichi Shiratori

Nasu Michihiro

Kokura Memorial Hospital

Masakiyo Nobuyoshi

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Hitoshi Okabayashi

Hitoshi Yasumoto

Jyota Nakano

Koto Memorial Hospital

Tomoyuki Murakami

Katsuya Ishida

Kumamoto University Hospital

Hisao Ogawa

Michio Kawasuji

Seigo Sugiyama

Shoichiro Hagiwara

Kurashiki Central Hospital

Kazuaki Mitsudo

Tatsuhiko Komiya

Kazushige Kadota

Kyoto University Hospital

Takeshi Kimura

Masashi Komeda

Maizuru Kyosai Hospital

Ryozo Tatami

Teruaki Ushijima

Mitsubishi Kyoto Hospital

Akira Yoshida

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Hiroyuki Nakajima

Shinji Miki

Nara Hospital, Kinki University School of Medicine

Ryuichi Hattori

Noboru Nishiwaki

Manabu Shirotani

Nishi-Kobe Medical Center

Hiroshi Kato

Hiroshi Eizawa

Osaka Red Cross Hospital

Masaru Tanaka

Kazuaki Minami

Shiga University of Medical Science Hospital

Minoru Horie

Tohru Asai

Hiroyuki Takashima

Ryuji Higashita

Shimabara Hospital

Mamoru Takahashi

Takafumi Tahata

Yoshiki Matoba

Shimada Municipal Hospital

Kiyoshi Doyama

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Makoto Araki

Shizuoka City Shizuoka Hospital

Akinori Takizawa

Mitsuomi Shimamoto

Fumio Yamazaki

Shizuoka General Hospital

Osamu Doi

Hirofumi Kambara

Katsuhiko Matsuda

Satoshi Kaburagi

Masafumi Nara

Takanohara Central Hospital

Masaki Kawanami

Tenri Hospital

Takashi Konishi

Kazunobu Nishimura

Seiji Ootani

Takaaki Sugita

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Appendix B. List of clinical research coordinators

Kumiko Kitagawa, Hiromi Yoshida, Misato Yamauchi, Asuka Saeki, Chikako Hibi, Emi

Takinami, Izumi Miki, Miya Hanazawa, Naoko Okamoto, Sachiko Maeda, Saeko

Minematsu, Saori Tezuka, Yuki Sato, Yumika Fujino, Hitomi Sasae, Rei Fujita, Ayu

Motofusa, Takami Hiraoka, Ayumi Yamamoto, Miho Hayashikawa, and Yoko Fujiki

A.J.S. Coats , MD

Editor-in-Chief: INTERNATIONAL JOURNAL OF CARDIOLOGY

October, 2008

Dear Professor A.J.S. Coats:

Please find our manuscript entitled “Chronic Obstructive Pulmonary Disease—an Independent Risk Factor for Long-term Cardiac and Cardiovascular Mortality in Patients with Ischemic Heart Disease” by Kei Nishiyama et al., which we would like to submit for publication as original research papers. Chronic obstructive pulmonary disease (COPD) and ischemic heart disease (IHD) share smoking as a risk factor, so these two diseases often coexist. Previous studies have shown patients with COPD have a significantly higher risk of long-term all-cause mortality after having PCI and CABG. This study also demonstrated patients with COPD also have higher long-term mortality rates than those without COPD after first elective PCI and CABG. The question of how having COPD affect long-term mortality and morbidity in patients with ischemic heart disease remains unsettled. To our knowledge, this study is the first

report showing patients with COPD have a significantly higher risk of cardiac death and cardiovascular death after having PCI and CABG.

The manuscript has not been published and is not being considered for publication elsewhere in whole or part in any language. All authors have read and approved the manuscript. No conflict of interests exists in any of the authors in this study.

Your kind consideration would be greatly appreciated.

Yours sincerely,

Kei Nishiyama, MD

Department of Cardiovascular Medicine,

Kyoto University Graduate School of Medicine,

54 Shogoinkawahara-cho, Sakyo-ku,

Kyoto, 606-8507, Japan


(Tel) 81-7-5751-3198

(Fax) 81-7-5751-3299


(E-mail) keinishi@kuhp.kyoto-u.ac.jp

Figure 1


[Click here to download high resolution image](#)



	1 Yr	2 Yrs	3 Yrs	4 Yrs
With COPD	91.4%	85.3%	82.8%	78.5%
n 234	211	194	141	74
Without COPD	97.2%	94.8%	92.3%	90.8%
n 9431	9056	8611	6287	3298



	1 Yr	2 Yrs	3 Yrs	4 Yrs
With COPD	95.2%	92.3%	91.7%	89.3%
n 234	211	194	144	74
Without COPD	98.2%	96.8%	95.4%	94.8%
n 9431	9056	8611	6287	3298



	1 Yr	2 Yrs	3 Yrs	4 Yrs
With COPD	95.6%	93.3%	92.1%	89.7%
n 234	211	194	144	74
Without COPD	98.6%	97.6%	96.6%	96.2%
n 9431	9056	8611	6287	3298

Table 1. Patient and Disease Characteristics

	COPD				p-value
	Yes		No		
	(n=240)		(n=9632)		
	n	%	n	%	
Having PCI	166	69.2%	6709	69.7%	0.8715
Female gender	42	17.5%	2855	29.6%	<0.0001
Emergency procedure	12	5.0%	532	5.4%	0.7212
Proir myocardial infarction	71	29.7%	2476	25.7%	0.1730
Congestive heart failure	51	21.3%	1216	12.7%	0.0003
Stroke	54	22.5%	1587	16.5%	0.0177
Peripheral artery disease	38	15.8%	1101	11.4%	0.0447
Chronic atrial fibrillation	20	8.3%	653	6.8%	0.5787
Malignancy	23	9.6%	680	7.1%	0.1523
Hypertension	150	62.5%	6657	69.2%	0.0303
Diabetes without insulin therapy	59	24.6%	2957	30.7%	0.0491
Diabetes with insulin therapy	17	7.1%	223	8.3%	0.4770
Dialysis	5	2.1%	402	4.2%	0.0769
Chronc kidney disease	137	58.8%	3775	40.4%	<0.0001
Anemia	77	32.5%	2458	26.1%	0.0320
Current smoker status	105	43.8%	3375	35.7%	0.5340
Left ventricular dysfunction	31	14.2%	708	8.1%	0.0031
Chronic total occulusion of coronary artery	80	33.3%	2941	30.5%	0.3759
Proximal left anterior descending coronary artery disease	171	71.3%	6916	71.8%	0.8453
Left main coronary artery disease	22	9.2%	933	9.7%	0.7851
Triple vessel disease	80	33.3%	3123	31.6%	0.7691
	COPD				p-value
	Yes		No		
	(n=240)		(n=9632)		
Age	72.7 ± 7.95		67.2 ± 10.00		<0.0001
Body mass index	21.7 ± 3.7		23.7 ± 3.2		<0.0001

COPD = chronic obstructive pulmonary disease; PCI = percutaneous coronary intervention.

Table 3. Cox Proportional-Hazards Model for All-cause Mortality and Cardiac Death

Clinical Outcomes	<i>Not-adjusted</i>			<i>Adjusted</i>		
	HR	95% CI	p-value	HR	95% CI	p-value
All-Cause mortality (n=906)	1.60	1.38-1.83	<0.0001	1.36	1.16-1.57	0.0003
Cardiac death (n=376)	1.65	1.31-2.02	0.0002	1.45	1.14-1.81	0.004

HR = hazard ratio; CI = confidential index.

Table 2. In-hospital Outcomes

Clinical Outcomes	COPD		p-value
	Yes (n=240)	No (n=9632)	
In-hospital death	3 1.3%	118 1.2%	0.9724
In-hospital QMI	2 0.8%	91 0.9%	0.8572
MACE	7 2.9%	235 2.4%	0.6464
Hospitalization (days)	22.6±29.6	18.1±21.7	0.0034

COPD = chronic obstructive pulmonary disease; QMI = Q-wave myocardial infarction; MACE = major adverse cardiac event.